) touched a new 52-week high of $50.50 on Wednesday, May 15, 2013
following strong annual results of Alliance Boots GmbH. Walgreens
has a 45% equity ownership stake in the European pharmacy-led,
health and wellbeing retailer Alliance Boots. The closing price
of $50.03 of the largest drug store chain in the U.S. represents
a solid year-to-date return of 32.1%.
AMERISOURCEBRGN (ABC): Free Stock Analysis
CARDINAL HEALTH (CAH): Free Stock Analysis
CVS CAREMARK CP (CVS): Free Stock Analysis
WALGREEN CO (WAG): Free Stock Analysis Report
To read this article on Zacks.com click here.
The Stock Driver
On Wednesday, Alliance Boots reported its annual results for the
year ended Mar 31, 2013. The 12.7% rise in Alliance Boots'
underlying profit was seen to boost market sentiments for its
minority stakeholder Walgreens as the stock rose 0.89% during
As per management at Alliance Boots, the companies are
progressing in a timely manner for the joint synergy program.
Walgreens is on track to attain synergies across joint operations
to be between $100-$150 million in the first year and $1 billion
by the end of 2016. The company expects the Alliance Boots deal
to be accretive to its adjusted EPS by 18-22 cents in fiscal
Nonetheless, the announcement from across the Atlantic is not the
only upside for Walgreens. Of late, the company looks to be in an
upturn following a string of strategic maneuvers. Earlier this
week, Walgreens extended its agreement as a network pharmacy
provider in the
) pharmacy benefit management (PBM) retail network. The deal
provided some positive momentum to the stock.
In March, Walgreens and Alliance Boots inked a 10-year deal with
), effective Sep 1, 2013, to improve global pharmaceutical supply
chain for branded as well as generic drugs. AmerisourceBergen
will replace Walgreens' current pharmaceutical distributor
) as the existing contract is set to expire in Aug 2013. The
company and Alliance Boots also have the right to purchase a
minority stake (of 7%) in AmerisourceBergen, exercisable up to
Given Walgreens' recent efforts that boost its growth prospects,
the stock received a series of positive estimate revision.
However, lingering bearish sentiments, reflected in a few
downward estimate revisions, weigh on the stock. The stock
carries a Zacks Rank #3 (Hold). While we remain on the sidelines
for Walgreens, CVS Caremark, carrying a Zacks Rank #2 (Buy)
warrants a look.